Back grey_arrow_rt.gif
Rosiglitazone lowers insulin resistance in nondiabetics
  NEW YORK (Reuters Health) - Rosiglitazone treatment results in an increase in insulin sensitivity in nondiabetic insulin-resistant individuals, researchers report in the August issue of Diabetes. This, they suggest, might prevent progression to diabetes.
"Insulin-resistant individuals are able to maintain normal glucose tolerance at the expense of compensatory hyperinsulinemia," senior investigator Dr. Gerald M. Reaven told Reuters Health. "The results of this study indicated that rosiglitazone-induced insulin sensitivity was associated with a return towards normal of the glucose-stimulated insulin secretory dose response curve."
Dr. Reaven of Stanford University School of Medicine, California and colleagues studied 14 insulin-resistant, predominantly overweight, nondiabetic subjects who were given 4 mg of rosiglitazone daily for 4 weeks, and then 8 mg daily for a further 8 weeks.
After treatment, insulin sensitivity increased and there was a significant reduction in steady-state plasma glucose level (from 13.5 mmol/L to 9.8 mmol/L). In addition, during graded insulin infusion, the glucose-stimulated insulin secretion rate decreased by 21% and the insulin metabolic clearance rate increased by 21%.
"By restoring more normal pancreatic beta-cell function," Dr. Reaven concluded, "these findings support the view that the decompensation in beta-cell function that heralds the transition from insulin resistance to frank diabetes could be prevented by such treatment of nondiabetic, insulin resistant persons."
Diabetes 2005;54:2247-2252.
  icon paper stack View Older Articles   Back to Top